Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Clin Cancer Res. 2018 Jun 25;24(19):4845–4853. doi: 10.1158/1078-0432.CCR-18-0864

Figure 6.

Figure 6

A) USC-ARK2 tumor growth inhibition in vivo, following 28 days dosing GS-5829 or JQ1. B) Individual tumor mass of USC-ARK2 xenograft model, recorded on day 28, after dosing GS-5829 or JQ1. C) USC-ARK1 tumor growth inhibition in vivo, following 19 days dosing GS-626510.